Binding specificity of a class II-restricted hepatitis B epitope by DR molecules from responder and nonresponder vaccine recipients

Human Immunology

Volumn 59, Issue 12, 1998, Pages 783-793

  Schuenke, Kimberly W ^a   Cook, Richard G ^a   Rich, Robert R ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HLA A ANTIGEN; HLA ANTIGEN CLASS 2; HLA B ANTIGEN; HLA C ANTIGEN; HLA DQ ANTIGEN; HLA DR4 ANTIGEN; SYNTHETIC PEPTIDE; T LYMPHOCYTE RECEPTOR; TETANUS TOXOID;

ALLELE; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; B LYMPHOCYTE; BINDING KINETICS; BIOSENSOR; CONTROLLED STUDY; DISSOCIATION CONSTANT; HEPATITIS B; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MONONUCLEAR CELL; PRIORITY JOURNAL; STOICHIOMETRY; T LYMPHOCYTE; VACCINATION;

ALLELES; BIOSENSING TECHNIQUES; CLONING, MOLECULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HISTOCOMPATIBILITY ANTIGENS CLASS II; HISTOCOMPATIBILITY TESTING; HLA-DR ANTIGENS; HLA-DR4 ANTIGEN; HUMANS; IMMUNODOMINANT EPITOPES; KINETICS; PEPTIDES; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 0032401006     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0198-8859(98)00072-X     Document Type: Article

References (40)

1. Nouri-Aria K.T., Magrin S., Alexander G.J.M., Anderson M.G., Williams R., Eddleston A.L.W.F. Abnormal T-cell activation in chronic hepatitis B infection a consequence of monocyte dysfunction? Immunol. 64:1988;733.
2. Salazar M., Deulofeut H., Granja C., Deulofeut R., Yunis D.E., Marcus-Bagley D., Awdeh Z., Alper C.A., Yunis E.J. Normal HBsAg presentation and T-cell defect in the immune response of nonresponders. Immunogenetics. 41:1995;366.
3. + suppressor T cells. Human Immunol. 22:1988;9.
4. Barnaba V., Franco A., Alberti A., Benvenuto R., Balsano F. Selective killing of hepatitis B envelope antigen-specific B cells by class I-restricted, exogenous antigen-specific T lymphocytes. Nature. 345:1990;258.
5. Vingerhoets J., Vanham G., Kestens L., Penne G., Leroux-Roels G., Gigase P. Deficient T-cell responses in non-responders to hepatitis B vaccination absence of TH1 cytokine production . Immunol Lett. 39:1994;163.
6. Alper C.A., Kruskall M.S., Marcus-Bagley D., Craven D.E., Katz A.J., Brink S.J., Dienstag J.L., Awdeh Z., Yunis E.J. Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med. 321:1989;708.
7. Egea E., Iglesias A., Salazar M., Morimoto C., Kruskall M.S., Awdeh Z., Schlossman S.F., Alper C.A., Yunis E.J. The cellular basis for lack of antibody response to hepatitis B vaccine in humans. J Exp Med. 173:1991;531.
8. Hatae K., Kimura A., Okubo R., Watanabe H., Erlich H.A., Ueda K., Nishimura Y., Sasazuki T. Genetic control of nonresponsiveness to hepatitis B vaccine by an extended HLA haplotype. Eur J Immunol. 22:1992;1899.
9. Desombere I., Hauser P., Rossau R., Paradijs J., Leroux-Roels G. Nonresponders to hepatitis B vaccine can present envelope particles to T lymphocytes. J Immunol. 154:1995;520.
10. Milich D.R., Leroux-Roels G.G., Louie R.E., Chisari F.V. Genetic regulation of the immune response to hepatitis B surface antigen (HBsAg). IV. Distinct H-2 linked Ir genes control antibody responses to different HBsAg determinants on the same molecule and map to the I-A and I-C sub-regions. J Exp Med. 159:1984;41.
11. Stern L.J., Wiley D.C. The human class II MHC protein HLA-DR1 assembles as empty αβ heterodimers in the absence of antigenic peptide. Cell. 68:1992;465.
12. Edwards P.R., Gill A., Pollard-Knight D.V., Hoare M., Buckle P.E., Lowe P.A., Leatherbarrow R.J. Kinetics of protein-protein interactions at the surface of an optical biosensor. Anal Biochem. 231:1995;210.
13. Davis J.E., Rich R.R., Van M., Le H.V., Pollack M.S., Cook R.G. Defective antigen presentation and novel structural properties of DR1 from an HLA haplotype associated with 21-hydroxylase deficiency. J Clin Invest. 80:1987;998.
14. Kropshofer H., Bohlinger I., Max H., Kalbacher H. Self and foreign peptides interact with intact and disassembled MHC class II antigen HLA-DR via tryptophan pockets. Biochem. 30:1991;9177.
15. Edwards P.R., Leatherbarrow R.J. Determination of association rate constants by an optical biosensor using initial rate analysis. Anal Biochem. 246:1997;1.
16. Kalandadze A., Galleno M., Foncerrada L., Strominger J.L., Wucherpfennig K.W. Expression of recombinant HLA-DR2 molecules. J Biol Chem. 271:1996;20156.
17. Schierle A., Tackacs B., Kremer L., Marin F., Sinigaglia F. Peptide binding to soluble HLA-DR4 molecules produced by insect cells. J Immunol. 149:1992;1994.
18. Roche P.A., Cresswell P. High-affinity binding of an influenza hemagglutinin-derived peptide to purified HLA-DR. J Immunol. 144:1990;1849.
19. Kropshofer H., Vogt A.B., Hammerling G.J. Structural features of the invariant chain fragment CLIP controlling rapid release from HLA-DR molecules and inhibition of peptide binding. Proc Natl Acad Sci USA. 93:1995;8313.
20. Liang M.N., Beeson C., Mason K., McConnell H.M. Kinetics of the reactions between the invariant chain (85-99) peptide and proteins of the murine class II MHC. Int Immunol. 7:1995;1397.
21. Sadegh-Nasseri S., Stern L.J., Wiley D.C., Germain R.N. MHC class II function preserved by low-affinity peptide interactions preceding stable binding. Nature. 370:1994;647.
22. Newton-Nash D.K., Eckels D.D. Differential effect of polymorphism at HLA-DR1 β-chain positions 85 and 86 on binding and recognition of DR1-restricted antigens. J Immunol. 150:1993;1813.
23. Dessen A., Lawrence C.M., Cupo S., Zaller D.M., Wiley D.C. X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II. Immunity. 7:1997;473.
24. Stern L.J., Brown J.H., Jardetzky T.S., Gorga J.C., Urban R.G., Strominger J.L., Wiley D.C. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature. 368:1994;215.
25. Signorelli K.L., Watts L.M., Lambert L.E. The importance of DR4Dw4 β chain residues 70, 71, and 86 in peptide binding and T cell recognition. Cell Immunol. 162:1995;217.
26. Alper C.A. The human immune response to hepatitis B surface antigen. Exp Clin Immunogenet. 12:1995;171.
27. Celis E., Karr R.W. Presentation of an immunodominant T-cell epitope of hepatitis B surface antigen by the HLA-DPw4 molecule. J Virol. 63:1989;747.
28. Min W.-P., Kamikawaji N., Mineta M., Tana T., Kashiwagi S., Sasazuki T. Identification of an epitope for T-cells correlated with antibody response to hepatitis B surface antigen vaccinated humans. Human Immunol. 46:1996;93.
29. + surface phenotype and a T helper type 1 profile of cytokine secretion in the liver of patients chronically infected with hepatitis B virus. J Immunol. 152:1994;3074.
30. Chelvanayagam G. A roadmap for HLA-DR peptide binding specificities. Human Immunol. 58:1997;61.
31. Rothbard J.B., Gefter M.L. Interactions between immunogenic peptide and MHC proteins. Annu Rev Immunol. 9:1991;527.
32. Kropshofer H., Hammerling G.J., Vogt A.B. How HLA-DM edits the MHC class II peptide repertoire survival of the fittest? Immunol Today. 18:1997;77.
33. Tampe R., Clark B.R., McConnell H.M. Energy transfer between two peptides bound to one MHC class II molecule. Science. 254:1991;87.
34. Weber D.A., Evavold B.D., Jensen P.E. Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM. Science. 274:1996;618.
35. Khilko S.N., Jelonek M.T., Corr M., Boyd L.F., Bothwell A.L.M., Margulies D.H. Measuring interactions of MHC class I molecules using surface plasmon resonance. J Immunol Methods. 183:1995;77.
36. Sadegh-Nasseri S., Germain R.N. How MHC class II molecules work peptide-dependent completion of protein folding . Immunol Today. 13:1992;43.
37. Rabinowitz J.D., Liang M.N., Tate K., Lee C., Beeson C., McConnell H.M. Specific T cell recognition of kinetic isomers in the binding of peptide to class II major histocompatibility complex. Proc Natl Acad Sci USA. 94:1997;8702.
38. Bluestone J.A., Kaliyaperumal A., Jameson S., Miller S., Dick R. II. Peptide-induced changes in class I heavy chains alter allorecognition. J Immunol. 151:1993;3943.
39. Rabinowitz J.D., Beeson C., Wulfing C., Tate K., Allen P.M., Davis M.M., McConnell H.M. Altered T cell receptor ligands trigger a subset of early T cell signals. Immunity. 5:1996;125.
40. De Magistris M.T., Alexander J., Coggeshall M., Altman A., Gaeta F.C.A., Grey H.M., Sette A. Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell. 68:1992;625.